MedTrace Logo

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

NCT06971913 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-05-14

No results posted yet for this study

Summary

This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.

Conditions

  • SLE (Systemic Lupus)
  • CMV

Interventions

DRUG

Interleukin-2 (IL-2)

Low-dose IL-2 at 1MIU will be administered subcutaneously every other day from baseline to CMV negativity.

DRUG

Ganciclovir (GCV)

Ganciclovir injection will be administrated intravenously at a dose of 5mg/kg per day.

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-20
Primary Completion
2025-09-30
Completion
2025-12-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06971913 on ClinicalTrials.gov